On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...

An auto-recruit program improved DXA screening and bone health management in men with prostate cancer receiving androgen-deprivation therapy.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

A MAN suffering from a common cancer was forced to have his entire penis amputated after it spread to his manhood, in what ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

A popular biological psychological explanation is the "Extreme Male Brain Theory" (EMB), which suggests that an overdose of prenatal androgen (male hormone) leads to the hyper-masculine brain type ...